The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Nylaspeg pegfilgrastim BiosimilarAdditional monitoring | Qilu Pharma Spain S.L. | Chemotherapy-Induced Febrile Neutropenia; Neutropenia | 🇪🇺 EU 2026-06-25 | Order → |
| Ogivri Biosimilar | Mylan S.A.S. | 🇪🇺 EU | Order → | |
| Ohtuvayre ensifentrine | Verona Pharma Ireland Limited | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU | Order → |
| Omblastys iodine (131I) omburtamab Orphan | Y-Mabs Therapeutics A/S | Neuroblastoma | 🇪🇺 EU 2022-12-15 | Order → |
| Omforro midazolam | Regulatory Pharma Net S.r.l. | Conscious Sedation; Anesthesia | 🇪🇺 EU | Order → |
| Omontys peginesatide Conditional | Takeda Global Research and Development Centre (Europe) | Anemia | 🇪🇺 EU | Order → |
| Oncophage Orphan | Antigenics Therapeutics Limited | 🇪🇺 EU | Order → | |
| Onswik Insulin efsitora alfa | Eli Lilly Nederland B.V. | Diabetes Mellitus | 🇪🇺 EU 2026-06-25 | Order → |
| Onzeald etirinotecan pegol | Nektar Therapeutics UK Limited | Breast Neoplasms | 🇪🇺 EU 2017-11-09 | Order → |
| Opaxio | CTI Life Sciences Ltd | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU | Order → |
| Oportuzumab monatox DLRC Pharma Services oportuzumab monatox | DLRC Pharma Services Ltd | Urologic Neoplasms; Urinary Bladder Neoplasms | 🇪🇺 EU | Order → |
| Opsiria sirolimus | Santen Oy | Uveitis | 🇪🇺 EU | Order → |
| OraNera | CellSeed Europe Ltd | Corneal Diseases | 🇪🇺 EU | Order → |
| Orathecin rubitecan Orphan | EuroGen Pharmaceuticals Ltd | Pancreatic Neoplasms | 🇪🇺 EU | Order → |
| orBec beclomethasone dipropionate Orphan | DOR BIOPHARMA UK Ltd | Graft vs Host Disease | 🇪🇺 EU | Order → |
| Orblid bevacizumab Orphan | Laboratoires Delbert | Telangiectasia, Hereditary Hemorrhagic | 🇪🇺 EU | Order → |
| Orepaxam treprostinil diolamine Orphan | Ferrer Internacional S.A. | Hypertension, Pulmonary | 🇪🇺 EU | Order → |
| Orplatna satraplatin | Pharmion Ltd. | Prostatic Neoplasms | 🇪🇺 EU | Order → |
| Ozespa briakinumab | Abbott Laboratories Ltd. | Psoriasis | 🇪🇺 EU | Order → |
| Parsaclisib Incyte Biosciences Distribution B.V. parsaclisib | Incyte Biosciences Distribution B.V. | 🇪🇺 EU | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.